42 followers
Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings https://t.co/0faInOkBhK https://t.co/L56z3NGorp
Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings https://t.co/0faInOkBhK https://t.co/L56z3NGorp
New article: Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings https://t.co/smZmW2WH6N #lungcancer #oncology https://t.co/ukPWlfF88